TD Waterhouse Canada’s DiaMedica Therapeutics DMAC Stock Holding History

TD Waterhouse Canada’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.97K	Hold	1,070	–	–	﹤0.01%	1882
2026 Q1	$6.83K	Hold	1,070	–	–	﹤0.01%	1845
2025 Q4	$8.51K	Hold	1,070	–	–	﹤0.01%	1588
2025 Q3	$7.34K	Hold	1,070	–	–	﹤0.01%	1610
2025 Q2	$3.81K	Hold	1,070	–	–	﹤0.01%	1640
2025 Q1	$3.96K	Hold	1,070	–	–	﹤0.01%	1582
2024 Q4	$5.8K	Hold	1,070	–	–	﹤0.01%	1524
2024 Q3	$4.45K	Hold	1,070	–	–	﹤0.01%	1520
2024 Q2	$3.12K	Hold	1,070	–	–	﹤0.01%	1586
2024 Q1	$3.88K	Hold	1,070	–	–	﹤0.01%	1579
2023 Q4	$4.05K	Sell	1,070 -500	-32%	-$1.24K	﹤0.01%	1408
2023 Q3	$4.81K	Hold	1,570	–	–	﹤0.01%	1370
2023 Q2	$8.11K	Hold	1,570	–	–	﹤0.01%	1289
2023 Q1	$3.1K	Hold	1,570	–	–	﹤0.01%	1456
2022 Q4	$2.91K	Hold	1,570	–	–	﹤0.01%	1438
2022 Q3	$2.41K	Hold	1,570	–	–	﹤0.01%	1480
2022 Q2	$3.89K	Hold	1,570	–	–	﹤0.01%	1436
2022 Q1	$4.68K	Sell	1,570 -270	-15%	-$766	﹤0.01%	1460
2021 Q4	$8.33K	Buy	+1,840	New	+$7.22K	﹤0.01%	1375

Other funds holding DMAC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Members Wealth Media, Pennsylvania $182M AUM 15.09% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

MWM

Meridian Wealth Management Lexington, Kentucky $3.25B AUM 41% 1-Year Est. Return

Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return

CFP

Catalyst Financial Partners Boston, Massachusetts $1.01B AUM 36.54% 1-Year Est. Return

TD Waterhouse Canada's DMAC Position: Q2 2026 in Review

TD Waterhouse Canada held its DiaMedica Therapeutics (DMAC) position steady in Q2 2026 at 1,070 shares worth $7.97K. The position accounts for ﹤0.01% of the portfolio, ranked #1882.

TD Waterhouse Canada first reported a position in DMAC in Q4 2021 and has held it in 19 quarters since. The position peaked at $8.51K in Q4 2025. 30 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

TD Waterhouse Canada held 1,070 shares of DiaMedica Therapeutics worth $7.97K as of Q2 2026.
TD Waterhouse Canada left its DiaMedica Therapeutics share count unchanged in Q2 2026.
DiaMedica Therapeutics made up ﹤0.01% of TD Waterhouse Canada's portfolio in Q2 2026, its #1882 holding.
TD Waterhouse Canada first reported a position in DiaMedica Therapeutics in Q4 2021 and has held it in 19 quarters since.
TD Waterhouse Canada's DiaMedica Therapeutics position peaked at $8.51K in Q4 2025.
30 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on TD Waterhouse Canada's 13F filing for Q2 2026, filed 27 Jul 2026.